Innopran XL (propranolol hydrochloride) is an extended-release formulation designed for the long-term management of hypertension and certain cardiovascular conditions. As a nonselective beta-adrenergic blocking agent, it offers sustained 24-hour blood pressure control with once-daily dosing. This medication works by reducing cardiac output and inhibiting renin release, providing consistent therapeutic effects. Clinical studies demonstrate its efficacy in both monotherapy and combination treatment regimens for hypertensive patients.

Features

• Extended-release formulation for 24-hour coverage
• Available in 80mg and 120mg strength capsules
• Once-daily dosing regimen
• FDA-approved for hypertension management
• Non-selective beta-blocker activity
• Compatible with many antihypertensive combinations

Benefits

• Provides consistent 24-hour blood pressure control
• Reduces cardiovascular strain and myocardial oxygen demand
• Lowers risk of hypertension-related complications
• Minimizes blood pressure variability throughout daily activities
• Offers convenient once-daily dosing for improved adherence
• Demonstrates proven efficacy in diverse patient populations

Common use

Innopran XL is primarily indicated for the management of hypertension. It may be used as monotherapy or in combination with other antihypertensive agents. Additionally, it’s prescribed for the prophylaxis of common migraine headaches and management of certain cardiac arrhythmias. The extended-release formulation is particularly beneficial for patients requiring stable beta-blockade throughout the 24-hour dosing interval.

Dosage and direction

The recommended starting dose for hypertension is 80mg once daily, preferably at bedtime. Dosage may be increased to 120mg once daily based on therapeutic response and tolerability. Maximum recommended dose is 120mg daily. Swallow capsules whole; do not crush, chew, or divide. Administration with food may enhance bioavailability. Dose adjustments are necessary for patients with hepatic impairment. Titration should occur at 3-7 day intervals.

Precautions

Monitor blood pressure and heart rate regularly during therapy. Use caution in patients with compensated heart failure. Abrupt discontinuation may cause rebound hypertension or angina exacerbation. Mask signs of hypoglycemia in diabetic patients. May exacerbate symptoms in patients with bronchospastic disease. Use cautiously in patients with peripheral vascular disease. Regular hepatic function monitoring recommended during long-term therapy.

Contraindications

Bronchial asthma or history of bronchospasm. Severe sinus bradycardia. Second- or third-degree heart block. Cardiogenic shock. Decompensated cardiac failure. Hypersensitivity to propranolol or any component of the formulation. Concurrent use with fluoxetine or other strong CYP2D6 inhibitors requiring careful consideration.

Possible side effect

Common effects include fatigue (10-15%), dizziness (5-10%), bradycardia (5-8%), and cold extremities (4-6%). Gastrointestinal disturbances such as nausea (3-5%) and diarrhea (2-4%) may occur. Less frequently, patients may experience sleep disturbances, depression, or exercise intolerance. Serious but rare side effects include bronchospasm, heart failure exacerbation, and severe bradycardia.

Drug interaction

Significant interactions occur with calcium channel blockers (additive bradycardia), digoxin (increased AV block risk), and insulin/oral hypoglycemics (masked hypoglycemia symptoms). CYP2D6 inhibitors (fluoxetine, paroxetine) may increase propranolol levels. Concomitant use with clonidine requires careful monitoring. NSAIDs may diminish antihypertensive effect. Alcohol may potentiate hypotensive effects.

Missed dose

If a dose is missed, take it as soon as remembered unless it’s nearly time for the next scheduled dose. Do not double the dose to make up for a missed dose. If multiple doses are missed, contact healthcare provider for guidance. Maintain regular dosing schedule to ensure consistent blood pressure control.

Overdose

Symptoms include severe bradycardia, hypotension, heart failure, bronchospasm, and hypoglycemia. Management involves gastric lavage if recent ingestion. Administer atropine for bradycardia. Glucagon may be effective for myocardial depression. Cardiac pacing may be necessary for heart block. Supportive care includes vasopressors for hypotension and bronchodilators for bronchospasm.

Storage

Store at controlled room temperature (20-25°C or 68-77°F). Protect from moisture and light. Keep in original container with tight closure. Do not store in bathroom medicine cabinet. Keep out of reach of children and pets. Do not use after expiration date printed on packaging.

Disclaimer

This information is for educational purposes only and does not replace professional medical advice. Always consult with a qualified healthcare provider before starting or changing medication regimens. Individual patient responses may vary. Proper diagnosis and monitoring are essential for safe and effective treatment.

Reviews

Clinical trials demonstrate 70-80% of patients achieve target blood pressure control with Innopran XL. Patients report improved quality of life due to consistent 24-hour coverage and convenient dosing. Healthcare providers appreciate its predictable pharmacokinetics and well-established safety profile. Long-term studies show maintained efficacy with minimal tolerance development over extended treatment periods.